23andme regeneron - Search News

Order byBest matchMost fresh

News

Regeneron buying 23andMe

Does the 23andMe Acquisition Make Regeneron a Buy Now?

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous market value. You might remember that the genetic testing company filed for Chapter 11 bankruptcy protections in March.

Continue reading

· 2h · on MSN

Regeneron buying 23andMe; What happened to 23andMe? Should I delete 23andMe data?

Regeneron Acquires 23andMe in $256M Deal

3d

Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Predictive Oncology breakthrough coincides with Regeneron Pharma’s acquisition of 23andMe for $256 million: Artificial intelligence meets genomics

Pittsburgh, Pennsylvania Saturday, May 24, 2025, 15:00 Hrs [IST] ...

3d

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results